Anthracycline-Sparing Strategies Help Refine HER2+ Breast Cancer Management
The treatment paradigm for HER2-positive breast cancer continues to evolve with a growing emphasis on anthracycline-sparing approaches and the refinement of initial strategies in both the early-stage and metastatic settings, according to Paolo Tarantino, MD. “I do feel the future will have more and more anthracycline-sparing [regimens], acknowledging that there are few selected populations of … Read more